Nucleonics discovers and develops novel, first-in-class RNAi therapeutics. The Company's clinical trials are essential to the evaluation of new therapies intended to address significant unmet medical needs.

Nucleonics is currently developing NUC B1000, an experimental, therapeutic candidate designed to treat chronic hepatitis B viral infection, utilizing RNAi. In May 2007, the FDA allowed clinical trials to proceed under Nucleonics' Investigational New Drug application. A Phase 1 clinical trial has been initiated at two sites in the United States (San Francisco, Chicago) and two sites in Eastern Europe. Additional sites in the United States are anticipated to be activated in 2008.

For more information on the NUC B1000 clinical trial, including trial details, eligibility, location and contact information, please contact: .

To view an informational animation that provides an overview of Nucleonics' experimental NUC B1000 therapeutic candidate and how it is intended to intervene in chronic hepatitis B viral infection, click on the link below: